Argent Biopharma Ltd (RGT) - Net Assets
Based on the latest financial reports, Argent Biopharma Ltd (RGT) has net assets worth AU$-8.63 Million AUD (≈ $-6.11 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$2.47 Million ≈ $1.75 Million USD) and total liabilities (AU$11.10 Million ≈ $7.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Argent Biopharma Ltd (RGT) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-8.63 Million |
| % of Total Assets | -349.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | -162.42% |
| 10-Year Change | -173.58% |
| Growth Volatility | 276.06 |
Argent Biopharma Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Argent Biopharma Ltd's net assets have evolved over time, based on quarterly financial data. Also explore RGT total asset value for the complete picture of this company's asset base.
Annual Net Assets for Argent Biopharma Ltd (2006–2025)
The table below shows the annual net assets of Argent Biopharma Ltd from 2006 to 2025. For live valuation and market cap data, see Argent Biopharma Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$-8.63 Million ≈ $-6.11 Million |
-48.16% |
| 2024-06-30 | AU$-5.82 Million ≈ $-4.12 Million |
+27.48% |
| 2023-06-30 | AU$-8.03 Million ≈ $-5.68 Million |
-255.06% |
| 2022-06-30 | AU$5.18 Million ≈ $3.67 Million |
-62.54% |
| 2021-06-30 | AU$13.83 Million ≈ $9.78 Million |
+346.81% |
| 2020-06-30 | AU$3.09 Million ≈ $2.19 Million |
-71.34% |
| 2019-06-30 | AU$10.80 Million ≈ $7.64 Million |
-14.91% |
| 2018-06-30 | AU$12.69 Million ≈ $8.98 Million |
-19.62% |
| 2017-06-30 | AU$15.79 Million ≈ $11.17 Million |
+34.61% |
| 2016-06-30 | AU$11.73 Million ≈ $8.30 Million |
+508.72% |
| 2015-06-30 | AU$1.93 Million ≈ $1.36 Million |
-57.64% |
| 2014-06-30 | AU$4.55 Million ≈ $3.22 Million |
-42.74% |
| 2013-06-30 | AU$7.94 Million ≈ $5.62 Million |
+908.96% |
| 2012-06-30 | AU$787.42K ≈ $557.15K |
+78.96% |
| 2012-04-30 | AU$440.00K ≈ $311.33K |
-46.88% |
| 2011-06-30 | AU$828.30K ≈ $586.08K |
+126.39% |
| 2010-06-30 | AU$-3.14 Million ≈ $-2.22 Million |
-35603.40% |
| 2009-06-30 | AU$-8.79K ≈ $-6.22K |
-100.45% |
| 2008-06-30 | AU$1.94 Million ≈ $1.37 Million |
-49.22% |
| 2007-06-30 | AU$3.81 Million ≈ $2.70 Million |
+38.08% |
| 2006-06-30 | AU$2.76 Million ≈ $1.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Argent Biopharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 117805.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$138.59 Million | % |
| Other Comprehensive Income | AU$295.76K | % |
| Total Equity | AU$-8.63 Million | 100.00% |
Argent Biopharma Ltd Competitors by Market Cap
The table below lists competitors of Argent Biopharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prima Cakrawala Abadi PT
JK:PCAR
|
$2.46 Million |
|
Lanesborough Real Estate Investment Trust
V:LRT-UN
|
$2.46 Million |
|
Biosergen AS
ST:BIOSGN
|
$2.46 Million |
|
Klarsen SA
PA:ALKLA
|
$2.47 Million |
|
CDN Maverick Capital Corp.
F:338B
|
$2.46 Million |
|
Fluicell AB
ST:FLUI
|
$2.45 Million |
|
MOBILUM TECHNOLOGIES INC.
F:C0B
|
$2.45 Million |
|
Infinitum Copper Corp
V:INFI
|
$2.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Argent Biopharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -5,152,448 to -8,629,925, a change of -3,477,477.
- Net loss of 17,844,295 reduced equity.
- New share issuances of 10,399,109 increased equity.
- Other comprehensive income decreased equity by 931,643.
- Other factors increased equity by 4,899,352.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-17.84 Million | -206.77% |
| Share Issuances | AU$10.40 Million | +120.5% |
| Other Comprehensive Income | AU$-931.64K | -10.8% |
| Other Changes | AU$4.90 Million | +56.77% |
| Total Change | AU$- | % |
Book Value vs Market Value Analysis
This analysis compares Argent Biopharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-06-30 | AU$0.00 | AU$0.04 | x |
| 2007-06-30 | AU$0.52 | AU$0.04 | x |
| 2008-06-30 | AU$0.24 | AU$0.04 | x |
| 2009-06-30 | AU$0.00 | AU$0.04 | x |
| 2010-06-30 | AU$-0.32 | AU$0.04 | x |
| 2011-06-30 | AU$0.07 | AU$0.04 | x |
| 2012-06-30 | AU$0.03 | AU$0.04 | x |
| 2013-06-30 | AU$0.12 | AU$0.04 | x |
| 2014-06-30 | AU$28.44 | AU$0.04 | x |
| 2015-06-30 | AU$6.81 | AU$0.04 | x |
| 2016-06-30 | AU$19.57 | AU$0.04 | x |
| 2017-06-30 | AU$16.80 | AU$0.04 | x |
| 2018-06-30 | AU$12.38 | AU$0.04 | x |
| 2019-06-30 | AU$9.06 | AU$0.04 | x |
| 2020-06-30 | AU$2.25 | AU$0.04 | x |
| 2021-06-30 | AU$7.26 | AU$0.04 | x |
| 2022-06-30 | AU$2.27 | AU$0.04 | x |
| 2023-06-30 | AU$-2.51 | AU$0.04 | x |
| 2024-06-30 | AU$-0.14 | AU$0.04 | x |
| 2025-06-30 | AU$-0.12 | AU$0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Argent Biopharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3058.43%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-75.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 6.81% | 51.23% | 0.07x | 1.94x | AU$-88.23K |
| 2007 | -2.14% | -3.11% | 0.55x | 1.26x | AU$-463.18K |
| 2008 | -96.93% | -98.51% | 0.72x | 1.36x | AU$-2.07 Million |
| 2009 | 0.00% | -92.17% | 0.13x | 0.00x | AU$-1.94 Million |
| 2010 | 0.00% | -748.06% | 0.02x | 0.00x | AU$-2.37 Million |
| 2011 | 233.63% | 5375.47% | 0.03x | 1.32x | AU$1.85 Million |
| 2012 | -36.94% | -548.83% | 0.05x | 1.26x | AU$-369.62K |
| 2013 | -9.65% | -2988.69% | 0.00x | 1.10x | AU$-1.56 Million |
| 2014 | -117.34% | -48525.59% | 0.00x | 1.09x | AU$-5.79 Million |
| 2015 | -197.10% | -64478.62% | 0.00x | 1.31x | AU$-3.99 Million |
| 2016 | -52.14% | -280252.34% | 0.00x | 1.39x | AU$-7.34 Million |
| 2017 | -50.17% | -6773.31% | 0.01x | 1.28x | AU$-9.77 Million |
| 2018 | -59.19% | -2778.66% | 0.01x | 1.44x | AU$-9.64 Million |
| 2019 | -100.46% | -1677.65% | 0.05x | 1.19x | AU$-12.11 Million |
| 2020 | -623.55% | -931.29% | 0.26x | 2.55x | AU$-19.67 Million |
| 2021 | -114.71% | -529.70% | 0.12x | 1.75x | AU$-17.25 Million |
| 2022 | -287.21% | -354.31% | 0.25x | 3.18x | AU$-17.35 Million |
| 2023 | 0.00% | -614.71% | 0.34x | 0.00x | AU$-20.08 Million |
| 2024 | 0.00% | -1967.34% | 0.08x | 0.00x | AU$-17.02 Million |
| 2025 | 0.00% | -3058.43% | 0.24x | 0.00x | AU$-16.98 Million |
Industry Comparison
This section compares Argent Biopharma Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $29,670,098
- Average return on equity (ROE) among peers: 4903.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Argent Biopharma Ltd (RGT) | AU$-8.63 Million | 6.81% | N/A | $2.46 Million |
| Althea Group Holdings Ltd (AGH) | $41.45 Million | -29.25% | 0.36x | $12.05 Million |
| BOD Science Ltd (BOD) | $3.47 Million | -155.95% | 0.53x | $3.01 Million |
| BPH Global Ltd (BP8) | $149.84K | 50079.24% | 22.90x | $2.62 Million |
| Cann Group Ltd (CAN) | $648.33K | -644.19% | 0.12x | $5.62 Million |
| ECS Botanics Holdings Ltd (ECS) | $319.74K | -109.87% | 0.16x | $5.65 Million |
| Ecofibre Ltd (EOF) | $109.94 Million | -13.34% | 0.36x | $5.36 Million |
| Epsilon Healthcare Ltd (EPN) | $2.99 Million | -68.61% | 4.98x | $5.51 Million |
| Elixinol Wellness Ltd (EXL) | $99.42 Million | 0.00% | 0.04x | $2.05 Million |
| IDT Australia Ltd (IDT) | $32.86 Million | 21.64% | 0.29x | $12.10 Million |
| Invion Ltd (IVX) | $5.46 Million | -46.66% | 0.11x | $3.70 Million |
About Argent Biopharma Ltd
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more